Literature DB >> 7070056

Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues.

D M Humphrey, L M McManus, K Satouchi, D J Hanahan, R N Pinckard.   

Abstract

Intradermal injection of 0.1 pmole (52 pg.) of acetyl glyceryl ether phosphorylcholine (AGEPC) in guinea pigs induced increased vascular permeability as assessed by a skin-blueing model. Rabbits and rats showed increased vascular permeability with 1.0 pmole (520 pg.) of AGEPC. On a molar basis, from 1,000 to 10,000 times more histamine was required to induce skin blueing in the same animals. In rabbits and guinea pigs, the increased vascular permeability induced by AGEPC occurred as an early, transient phase and as a delayed, prolonged phase. The early, transient phase was not inhibited by chlorpheniramine doses which markedly reduced or abrogated histamine-induced blueing. AGEPC was 100 to 1000 times more potent than histamine on a molar basis for the induction of vasoconstriction in a blued skin assay in guinea pigs. These studies demonstrate that AGEPC has potent vasoactive properties and provide additional information that implicates this acetylated alkyl phosphoglyceride as a mediator of the acute inflammatory process.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7070056

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  54 in total

1.  Increased permeability of microcarrier-cultured endothelial monolayers in response to histamine and thrombin. A model for the in vitro study of increased vasopermeability.

Authors:  J J Killackey; M G Johnston; H Z Movat
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

2.  Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart.

Authors:  G Montrucchio; G Alloatti; F Mariano; R de Paulis; A Comino; G Emanuelli; G Camussi
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

3.  Effects of serum albumin, indomethacin and histamine H1-antagonists on Paf-acether-induced inflammatory responses in the skin of experimental animals and man.

Authors:  C B Archer; D M MacDonald; J Morley; C P Page; W Paul; S Sanjar
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

4.  Effect of platelet-activating factor and serum-treated zymosan on prostaglandin E2 synthesis, arachidonic acid release, and contraction of cultured rat mesangial cells.

Authors:  D Schlondorff; J A Satriano; J Hagege; J Perez; L Baud
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

5.  Effect of PAF on rat lung vascular permeability: role of platelets and polymorphonuclear leucocytes.

Authors:  M G Sirois; W T de Lima; A J de Brum Fernandes; R J Johnson; G E Plante; P Sirois
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

6.  Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma.

Authors:  J Sörensen; B Kald; C Tagesson; M Lindahl
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

7.  Platelet involvement in rat paw edema induced by 2-methoxy-PAF.

Authors:  P M Silva; R S Cordeiro; M A Martins; M G Henriques; B B Vargaftig
Journal:  Inflammation       Date:  1986-12       Impact factor: 4.092

8.  Enhancement by cyclo-oxygenase inhibitors of platelet-activating factor production in thapsigargin-stimulated macrophages.

Authors:  M Watanabe; M Yamada; S Mue; K Ohuchi
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

9.  Protection of platelet-activating factor-induced acute renal failure by BN 52021.

Authors:  E Pirotzky; P Colliez; C Guilmard; J Schaeverbeke; J M Mencia-Huerta; P Braquet
Journal:  Br J Exp Pathol       Date:  1988-04

10.  Mechanism of action of platelet activating factor in the pulmonary circulation: an investigation using a novel isotopic system in rabbit isolated lung.

Authors:  J P Seale; S Nourshargh; P G Hellewell; T J Williams
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.